Skip to main content

Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Part of the Cancer Treatment and Research book series (CTAR,volume 179)

Abstract

The myeloproliferative neoplasms (MPNs) are clonal stem cell-derived diseases. This chapter focuses on the subcategory of Philadelphia (Ph) chromosome-negative classical MPNs, polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF). These MPNs are associated with both microvascular and macrovascular thrombosis, which may occur in the venous and arterial circulation. Erythrocytosis, leukocytosis, and increased JAK2V617F allele burden are known to be risk factors. In this chapter, we review the thrombotic and hemostatic manifestations of the Philadelphia (Ph) chromosome-negative classical MPNs, including the clinical manifestations, the pathophysiology, as well as management.

Keywords

  • Myeloproliferative neoplasms
  • Polycythemia vera
  • Essential thrombocythemia
  • Myelofibrosis
  • Microvascular thrombosis
  • Macrovascular thrombosis
  • JAK2V617F

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-20315-3_11
  • Chapter length: 20 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   79.99
Price excludes VAT (USA)
  • ISBN: 978-3-030-20315-3
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   99.99
Price excludes VAT (USA)
Hardcover Book
USD   139.99
Price excludes VAT (USA)

References

  1. Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122(13):2176–2184

    CAS  CrossRef  Google Scholar 

  2. Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29(5):573–582

    CAS  CrossRef  Google Scholar 

  3. Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. [Epub ahead of print 16 January 2018]

    Google Scholar 

  4. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232

    CrossRef  Google Scholar 

  5. Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33:313–320

    CAS  CrossRef  Google Scholar 

  6. McMahon B, Stein BL (2013) Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost 39(1):101–111

    Google Scholar 

  7. Gangat et al (2006) Abdominal vein thrombosis in ET: prevalence, clinical correlates and prognostic implications. Eur J Haematol 77:323–333

    CrossRef  Google Scholar 

  8. Smalberg et al (2012) Myeloproliferative neoplasms in Budd-Chiari Syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25):4921–4928

    CAS  CrossRef  Google Scholar 

  9. Carobbio et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857–5859

    CAS  CrossRef  Google Scholar 

  10. Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR (2013) Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma 54(9):1989–1995

    CAS  CrossRef  Google Scholar 

  11. Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR (2011) Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis (article ID 874146)

    Google Scholar 

  12. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of Thrombosis in WHO-ET (IPSET-Thrombosis). Blood 120(26):5128–5133

    CAS  CrossRef  Google Scholar 

  13. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R (2007) Leukocytosis as a major thrombotic risk factor in patients with PV. Blood 109(6):2446–2452

    CAS  CrossRef  Google Scholar 

  14. Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A (2017) The effect of arterial hypertension in low-risk polycythemia vera. Am J of Hematology 92(1):E5

    Google Scholar 

  15. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782

    CrossRef  Google Scholar 

  16. Barbui T et al (2009) Perspective on thrombosis in essential thrombocythemia: is leukocytosis a causative factor? Blood 114:759–763

    Google Scholar 

  17. Lancellotti S, Dragani A, Ranalli P, Petrucci G, Basso M, Tartaglione R, Rocca B, De Cristofaro R (2015) Qualitative and quantitative modifications of vWF In patients with ET and controlled platelet count. J Thromb Haemost 13:1226–1237

    CAS  CrossRef  Google Scholar 

  18. van Genderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH (1996) The reduction of large vWF multimers in plasma in ET is related to platelet count. Br J Haematol 93:962–965

    Google Scholar 

  19. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant’Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2380–2390

    CAS  CrossRef  Google Scholar 

  20. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant’antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M (2014) Jak2 or CALR mutation status defines subtypes of ET with substantially different clinical courses and outcomes. Blood 123(10):1544–1551

    Google Scholar 

  21. Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, Fabris F, Randi ML (2016) Thrombotic risk correlates with mutational status in ET. Eur J Clin Inv 46(8):683–689

    Google Scholar 

  22. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T (2007) Prospective identification of high-risk polycythemia vera patients based on Jak2V617F allele burden. Leukemia 21:1952–1959

    CAS  CrossRef  Google Scholar 

  23. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M (2014) Clinical effect of driver mutations of JAK2, CALR, and MPL in primary myelofibrosis. Blood 24(7):1062–1069

    CAS  CrossRef  Google Scholar 

  24. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL (2017) Clonal Hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377(2):111–121

    CrossRef  Google Scholar 

  25. Lussana F, Rambaldi A (2017) Inflammation and myeloproliferative neoplasms. J Autoimmun 85:58–63

    CAS  CrossRef  Google Scholar 

  26. Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A (2017) Driver mutations, pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol 10:54

    Google Scholar 

  27. Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of CRP and pentraxin 3. Hematologica 96(2):315–318

    Google Scholar 

  28. Vianello F, Battisti A, Cella G, Marchetti M, Falanga A (2011) Defining the thrombotic risk in patients with myeloproliferative neoplasms. Sci World J 11:1131–1137

    CrossRef  Google Scholar 

  29. Falanga A et al (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012:571–581

    PubMed  Google Scholar 

  30. Zhang W, Qi J, Zhao S, Shen W, Dai L, Han W, Huang M, Wang Z, Ruan C, Wu D, Han Y (2017) Clinical significance of circulating microparticles in Ph-myeloproliferative neoplasms. Oncol Lett 14:2531–2536

    CrossRef  Google Scholar 

  31. Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A (2008) Thrombin generation and APC resistance in patients with ET and PV. Blood 112(1):4061–4068

    CAS  CrossRef  Google Scholar 

  32. Tevet M, Ionescu R, Dragan C, Lupu AR (2015) Influence of the Jak2V617F mutation and inherited thrombophilia on the thrombotic risk among patients with myeloproliferative disorders. Maedica 10(1):27–32

    Google Scholar 

  33. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A (2016) Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol 91(4):390–394

    CrossRef  Google Scholar 

  34. Barbui et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol 29(6):761–769

    CrossRef  Google Scholar 

  35. Tefferi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874–1881

    CAS  CrossRef  Google Scholar 

  36. Finazzi G (2004) A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris) 52:285–288

    CAS  CrossRef  Google Scholar 

  37. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114–124

    CAS  CrossRef  Google Scholar 

  38. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065–3072

    CAS  CrossRef  Google Scholar 

  39. Gisslinger H, Zagrijtschuk O, Veronika B-A, Thaler J, Schloegl E, Guenther A. Gastl, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Nicole C. Them, Kadlecova P, Klade C, Greil R (2017) Ropeginterferon Alfa-2b Induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized control trial. In: The 59th annual meeting & exposition of the American Society of Hematology, Atlanta, GA, 9–12 Dec 2017. (Abstract nr 320)

    Google Scholar 

  40. Vannucchi AM (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426–435

    Google Scholar 

  41. Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C (2016) Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 101(8):926–931

    CAS  CrossRef  Google Scholar 

  42. Alvarez-Larran et al (2010) Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116(8):1205–1210

    CAS  CrossRef  Google Scholar 

  43. Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM (2017) Benefits and risks of antithrombotic therapy in essential thrombocythemia. Ann Intern Med 167:170–180

    CrossRef  Google Scholar 

  44. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332(17):1132–1136

    CAS  CrossRef  Google Scholar 

  45. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) Hydroxyurea compared with anagrelide in high-risk ET. N Engl J Med 353(1):33–45

    CAS  CrossRef  Google Scholar 

  46. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized control trial. Blood 121(10):1720–1728

    CAS  CrossRef  Google Scholar 

  47. Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF (2017) Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 130(17):1889–1897

    CAS  CrossRef  Google Scholar 

  48. Ellis MH, Lavi N, Vannucchi A, Harrison C (2014) Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. Thromb Res 134:251–254

    CAS  CrossRef  Google Scholar 

  49. Ianotto et al (2017) Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol 106:517–521

    CAS  CrossRef  Google Scholar 

  50. Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S (2017) The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case-based review. Leuk Res 58:14–22

    CrossRef  Google Scholar 

  51. Adami R (1993) Therapeutic thrombocytapheresis: a review of 132 patients. Int J Artif Organs 16(Suppl. 5):183–184

    CrossRef  Google Scholar 

  52. Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Micò C, Vannucchi AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A, Mazzucconi MG, Santoro C, Barbui T (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111:666–671

    CAS  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Raajit K. Rampal .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Sankar, K., Stein, B.L., Rampal, R.K. (2019). Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. In: Soff, G. (eds) Thrombosis and Hemostasis in Cancer. Cancer Treatment and Research, vol 179. Springer, Cham. https://doi.org/10.1007/978-3-030-20315-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-20315-3_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-20314-6

  • Online ISBN: 978-3-030-20315-3

  • eBook Packages: MedicineMedicine (R0)